Smith & Nephew (SNN) Earnings Date & Reports

Key Takeaways

• Smith & Nephew reported third quarter 2026 revenue of $1.551 billion, up 3.4% year over year on both a reported and underlying basis, an acceleration from the second quarter.
• Management lowered full-year 2026 guidance, now expecting underlying revenue growth of around 3% (previously around 4%) and trading profit of roughly $1.25 billion (previously around $1.3 billion).
• Sports Medicine & ENT (Ear, Nose and Throat) was the standout, growing 8.0% to $507 million, with Sports Medicine Joint Repair up 11.1% for a fourth consecutive quarter of double-digit growth.
• US Orthopaedics remained the weak spot, with US Knee Implants down 7.3% and US Hip Implants down 1.0%, offsetting international and robotics-driven strength.
• The company confirmed that discussions with Johnson & Johnson over a potential combination with its DePuy Synthes orthopaedics business have ended, though it continues to review strategic options for the unit.
• Its $500 million share buyback remains on track, with $250 million completed through the end of the third quarter.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional Tickeron pages.
• Discover Trending AI Robots to see AI-driven trading strategies currently gaining traction in the market.

Earnings Context and Why It Matters

Smith & Nephew's third quarter update carries outsized weight because it tests the company's ability to sustain momentum in fast-growing businesses while stabilizing its larger US orthopaedics franchise. Through the first half of 2026, investors rewarded strong Sports Medicine and Advanced Wound Management performance but remained cautious about softness in US hip and knee reconstruction. This update also resolved months of market speculation: the company confirmed it had approached Johnson & Johnson earlier in the year about a possible combination with its DePuy Synthes orthopaedics division, only for those talks to end. With growth accelerating but guidance reduced, the report sharpened the debate over whether Smith & Nephew's innovation pipeline can offset near-term headwinds.

Reported Results

Smith & Nephew reported third quarter 2026 revenue of $1.551 billion, up 3.4% from $1.501 billion a year earlier, with growth identical on a reported and underlying basis. The result represented an acceleration from the 1.6% underlying growth recorded in the second quarter.

By business unit, Sports Medicine & ENT grew 8.0% to $507 million, led by an 11.1% increase in Sports Medicine Joint Repair to $283 million and a 7.7% rise in Arthroscopic Enabling Technologies. Advanced Wound Management was broadly flat at $454 million, as a 10.7% increase in Advanced Wound Devices was offset by an 8.7% decline in Advanced Wound Bioactives, reflecting continued pressure from US reimbursement changes for skin substitutes. Orthopaedics returned to growth at $590 million, up 2.3%, with Other Reconstruction surging 43.8% on strong robotics-assisted CORI system placements.

However, US reconstruction remained under pressure, with US Knee Implants down 7.3% and US Hip Implants down 1.0%. Citing the outlook for US hips and knees in the fourth quarter, the company cut its full-year guidance: underlying revenue growth is now expected around 3% (previously around 4%), trading profit around $1.25 billion (previously around $1.3 billion), and free cash flow around $750 million (previously around $800 million).

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking medical technology names like Smith & Nephew, it can surface comparable opportunities and momentum signals across the broader healthcare and industrials landscape.

Market Reaction and Investor Sentiment

The market's initial reaction was measured but positive. Smith & Nephew shares rose in premarket trading following the update, with investors appearing to focus on the improving growth trajectory, resilient cash generation, and a deeper 2027 product pipeline rather than the guidance reduction. The confirmation that Johnson & Johnson discussions had ended removed a layer of uncertainty, though it also disappointed some investors who had hoped for a value-unlocking transaction in orthopaedics. Sentiment remains divided: bulls point to double-digit growth in Sports Medicine Joint Repair and the recovery in international orthopaedics, while bears emphasize persistent US knee and hip softness and the lower profit outlook heading into year-end.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should focus on whether Smith & Nephew's new product cycle can reverse its US orthopaedics weakness. The company received FDA (U.S. Food and Drug Administration) clearance for the cementless version of its LANDMARK knee system during the quarter, addressing a major portfolio gap as the market shifts toward cementless knees. A cemented LANDMARK version is expected in the second quarter of 2027.

Several additional catalysts are scheduled for 2027, including the CORI Hip robotic launch in the first quarter and the CORI Hip Impactor later in the year. In Advanced Wound Management, the key question is how quickly the skin substitute market normalizes following the reimbursement reset that began in 2026.

Strategic developments also remain in focus. Management said it continues to evaluate the full range of options for its Orthopaedics business after the Johnson & Johnson talks ended. Meanwhile, capital returns stay active, with the $500 million buyback halfway complete. Together, these factors mean the stock's near-term narrative will hinge on execution in US reconstruction and the pacing of its 2027 product launches, rather than any single quarterly print.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations